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Abstract
Corticosteroids directly affect the heart and vasculature and are implicated in 
the pathogenesis of heart failure. Attention is focussed upon the role of the 
mineralocorticoid receptor (MR) in mediating pro-fibrotic and other adverse effects 
of corticosteroids upon the heart. In contrast, the role of the glucocorticoid receptor 
(GR) in the heart and vasculature is less well understood. We addressed this in mice 
with cardiomyocyte and vascular smooth muscle deletion of GR (SMGRKO mice). 
Survival of SMGRKO mice to weaning was reduced compared with that of littermate 
controls. Doppler measurements of blood flow across the mitral valve showed an 
elongated isovolumetric contraction time in surviving adult SMGRKO mice, indicating 
impairment of the initial left ventricular contractile phase. Although heart weight was 
elevated in both genders, only male SMGRKO mice showed evidence of pathological 
cardiomyocyte hypertrophy, associated with increased myosin heavy chain-β expression. 
Left ventricular fibrosis, evident in both genders, was associated with elevated levels 
of mRNA encoding MR as well as proteins involved in cardiac remodelling and fibrosis. 
However, MR antagonism with spironolactone from birth only modestly attenuated 
the increase in pro-fibrotic gene expression in SMGRKO mice, suggesting that elevated 
MR signalling is not the primary driver of cardiac fibrosis in SMGRKO mice, and cardiac 
fibrosis can be dissociated from MR activation. Thus, GR contributes to systolic function 
and restrains normal cardiac growth, the latter through gender-specific mechanisms. 
Our findings suggest the GR:MR balance is critical in corticosteroid signalling in specific 
cardiac cell types.
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Introduction
Corticosteroids, mineralocorticoids and glucocorticoids, 
exert a variety of effects on the cardiovascular system. 
Excessive glucocorticoid levels, whether endogenous 
as in Cushing’s disease, or exogenous through 
pharmacotherapy, are associated with increased risk of 
cardiovascular disease and heart failure (Souverein et al. 
2004, Walker 2007). In contrast, physiological levels 
of glucocorticoids are important in the homeostatic 
regulation of the heart and vasculature (Richardson et al. 
2016). In Addison’s disease, insufficient glucocorticoid 
action leads to myocardial weakness and reduced 
cardiac output, though the underlying reasons are 
complex and remain poorly understood. In mice, long-
term adrenalectomy induces cardiac abnormalities 
that include enlarged hearts and impaired left 
ventricular (LV) function, both of which are rescued 
by glucocorticoid (corticosterone) replacement therapy 
(Cruz-Topete et al. 2016).
Endogenous glucocorticoids exert most of their 
actions through the closely related glucocorticoid 
receptor (GR) and mineralocorticoid receptor (MR). 
Cardiomyocytes lack the glucocorticoid-inactivating 
enzyme, 11β-hydroxysteroid dehydrogenase type 2 
(Chapman et al. 2013). Thus, the effects of glucocorticoids 
in cardiomyocytes are potentially mediated by both GR 
and MR. Both receptors are capable of binding to and 
activating many of the same target genes. Nevertheless, 
they play distinct, and sometimes opposing, roles 
in glucocorticoid action (Richardson  et  al. 2016). 
Elucidation of their respective physiological roles in the 
cardiovascular system is important to understand their 
pathophysiological relevance and may suggest new 
therapeutic approaches to cardiac disease.
Elevated MR signalling is pro-inflammatory in the 
heart and associates with cardiac fibrosis, inflammation 
and heart failure (Messaoudi et al. 2012, Young & Rickard 
2015). The effectiveness of MR antagonism in the 
treatment of heart failure has focussed its attention on the 
significance of MR activation in heart. However, deletion 
of MR in cardiomyocytes has a relatively minor impact 
on the heart in normal physiology (Fraccarollo  et  al. 
2011, Lother  et  al. 2011). Similarly, although vascular 
smooth muscle (VSM) MR knockout is protective against 
age-related hypertension and cardiac hypertrophy, it has 
negligible effect on blood pressure and heart size in young 
mice (<7  months of age) (McCurley  et  al. 2012). The 
physiological role of GR in the cardiovascular system has 
been less explored. We have previously shown an essential 
role for GR in maturing the foetal heart in preparation 
for life after birth. Hearts of foetal SMGRKO mice, which 
lack GR in cardiomyocytes and VSM, showed evidence of 
functional, structural and biochemical immaturity (Rog-
Zielinska et al. 2013). Consistent with this, glucocorticoid 
treatment of primary murine foetal cardiomyocytes, 
improved contractility, calcium handling and myofibril 
structure in a GR-dependent manner (Rog-Zielinska et al. 
2014a). Others have started to address the role of GR 
signalling in adult heart. Recent evidence in mice with 
MHCα-Cre-mediated deletion of GR in cardiomyocytes 
has demonstrated a tonic role for GR in preventing heart 
disease, with anti-inflammatory and pro-survival/anti-
apoptotic mechanisms implicated (Oakley et al. 2013).
Here, we aimed to establish the postnatal 
consequences of SM22α-Cre-driven deletion of GR in 
cardiomyocytes and VSM for cardiac function and 
remodelling using SMGRKO mice. We show that the 
isovolumetric contraction time is increased in adult male 
and female SMGRKO mice, demonstrating a homeostatic 
role for GR in normal systolic function in both genders. 
Heart mass is increased in adult mice of both genders, 
yet cardiomyocyte hypertrophy only develops in male, 
and not female SMGRKO mice, suggesting gender-
specific roles of glucocorticoids in the development 
of cardiomyocyte hypertrophy. In both genders, mice 
show evidence of cardiac fibrosis that is associated with 
increased expression of MR. However, MR antagonism 
only partially rescues the pro-fibrotic phenotype 
indicating that MR is not the primary driver of cardiac 
fibrosis in this model. SMGRKO mice may be a useful pre-
clinical model in which to investigate MR-independent 
pathways that drive cardiac fibrosis.
Materials and methods
Animals
All experiments involving animals were approved by 
the University of Edinburgh Animal Welfare and Ethical 
Review Body and were carried out in strict accord with 
accepted standards of humane animal care under the 
auspices of the Animal (Scientific Procedures) Act UK 
1986. SMGRKO mice were generated by crossing mice 
with loxP sites flanking exon 3 of the Nr3c1 gene encoding 
GR (GRfl/fl mice), congenic on a C57BL/6J genetic 
background, with SM22α-Cre transgenic mice as described 
previously (Rog-Zielinska et al. 2013). In all experiments, 
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Cre+ SMGRKO mice were compared with Cre− (control) 
littermates. Cardiac function was assessed at 10  weeks 
of age using a Visualsonics Vevo 770 High Resolution 
Ultrasound Scanner. Briefly, mice were anaesthetised 
with 2% isoflurane gas, and the parasternal long axis 
view was used to image the heart in M-mode and in ECG-
Gated Kilohertz Visualization (EKV) mode, whilst body 
temperature was maintained at 37°C and heart rate was 
maintained at ~450 bpm. Pulse-wave Doppler was used 
to measure blood flow across the mitral valve chamber 
using the apical four chamber view. Measurements were 
collected from the Doppler traces using Vevo 770 image 
analysis software. Mice were decapitated at 12 weeks of 
age and trunk blood was collected. Kidneys were weighed, 
snap frozen and stored at −80°C for subsequent RNA and 
protein analysis. Hearts from male mice were weighed 
then either fixed in 10% formalin for histological and 
immunohistochemical analysis or were snap frozen and 
stored at −80°C for subsequent RNA and protein analysis. 
Hearts from female mice were weighed and a 5 mm 
transverse segment of heart was fixed in 10% formalin. 
The remaining portions of the LV were snap frozen for 
mRNA and protein extraction. For retrograde cardiac 
perfusion-fixation, male mice were anaesthetised by 
intraperitoneal injection of 1 mg/kg medetomidine with 
75 mg/kg ketamine. The abdominal aorta was cannulated 
below the branch of the renal artery and perfused with 
heparinised PBS for 2 min followed by 10% formalin 
in PBS for 5 min. Hearts were dissected and fixed in 
10% formalin.
Spironolactone treatment
Male SMGRKO mice and control littermates were treated 
from birth with vehicle or 20 mg/kg/day spironolactone, 
an MR antagonist, administered in the drinking water 
to lactating dams until weaning then to offspring, 
according to a previous report (Ouvrard-Pascaud  et  al. 
2005). Animals were killed by cervical dislocation at 
8  weeks for organ collection. Tissues were collected as 
mentioned previously.
Ventricular cardiomyocyte isolation and  
volume measurement
Cardiomyocytes were isolated following retrograde 
Langendorff perfusion with collagenase type 1 (0.6 mg/mL, 
Worthington, New Jersey, USA) and protease type XIV 
(0.075 mg/mL, Sigma-Aldrich) in a modified Tyrode’s 
solution containing 134 mM NaCl, 11 mM Glucose, 
4 mM  KCl, 1.2 mM MgSO4, 1.2 mM Na2H2PO4, 10 mM 
HEPES, pH 7.34. Rod-shaped cardiomyocytes were 
collected in the same modified Tyrode’s solution but 
containing 108 mM NaCl with the addition of 50 mM 
taurine and 50 µM CaCl2. Cardiomyocyte volume was 
estimated from the cell membrane surface area (Page 
1978), calculated by applying a hyperpolarizing pulse 
(−10 mV) under voltage-clamp and integrating the 
resulting capacitive current, as described (Diaz et al. 1997).
Plasma corticosterone measurements
Plasma was obtained from blood samples collected from 
the tail vein of conscious mice at 07:00 h and 19:00 h 
and stored at −80°C prior to use. Corticosterone levels 
were measured using a colourimetric ELISA as described 
(Al-Dujaili et al. 2009).
Western blotting
Protein was extracted from left ventricle (LV) tissue 
by homogenising in protein extraction buffer (25 mM 
HEPES, 68.5 mM NaCl, 0.5 mM MgCl2, 0.5 mM CaCl2, 
5 mM NaF, 1 mM EDTA, 5 mM sodium pyrophosphate, 
1% NP-40, 10% glycerol, 1× protease inhibitor cocktail 
tablet). After centrifugation, protein concentration was 
measured relative to bovine serum albumin (Protein assay 
standard II, Bio-Rad) using Bradford assay. Protein samples 
(30 μg) were added to NuPAGE LDS Sample Buffer and 
NUPAGE Sample Reducing Buffer (both Thermo Fisher 
Scientific). Samples were denatured, electrophoresed on 
a NuPAGE Novex 4–12% Bis Tris gel in NuPAGE MES 
SDS running buffer (Thermo Fisher Scientific), and then 
transferred to a nitrocellulose membrane. The membrane 
was blocked with 5% BSA in Tris-buffered saline for 1 h, 
and then incubated with primary antibodies against GR 
(1:400; M-20, Insight Biotechnology, Middlesex, UK) and 
β-actin (1:10,000; 4967S Cell Signalling Technologies) at 
4°C overnight, washed and incubated with secondary 
antibodies: IRDye 800CW Goat anti-Rabbit IgG (1:10,000; 
926-32211 Licor Biosciences, Cambridge, UK) and IRDye 
800CW Goat anti-Mouse IgG (1:10,000; 926-32210 Licor 
Biosciences). An Odyssey infrared imaging system (Licor 
Biosciences) was used to measure GR protein levels relative 
to β-actin using Odyssey software.
qRT-PCR
RNA was extracted from LV tissue by homogenisation 
in TRIzol (Thermo Fisher Scientific) followed by 
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purification using a Purelink RNA mini kit (Thermo 
Fisher Scientific). cDNA was synthesised from 1 μg RNA 
using a SuperScript III Reverse transcriptase system kit 
(Thermo Fisher Scientific) then subject to quantitative 
(q)PCR (in triplicate) using the Roche Lightcycler 480 
system and universal probe library (Roche) with gene-
specific primer sets (Supplementary Table  1, see section 
on supplementary data given at the end of this article). A 
standard curve was prepared from pooled cDNA samples. 
Relative quantification was provided by LightCycler 
software using the maximum second derivative method 
and mRNA levels were normalised to the average of Actb 
and Gapdh mRNA levels.
Mouse fibrosis PCR array
cDNA was synthesised from 1µg mouse LV RNA using 
the RT2 First Strand Kit (Qiagen) according to the 
manufacturer’s instructions. cDNA was mixed with RT2 
Syber Green Mastermix prior to addition to the Mouse 
Fibrosis RT2 Profiler PCR Array plate (PAMM-120E, 
Qiagen). Plates were heated to 95°C for 10 min then 
underwent 40 cycles of amplification (95°C, 15 s then 
60°C, 1 min) using an Applied Biosystems 7900 Real-Time 
PCR System (Thermo Fisher Scientific). The threshold 
value was manually set and CT values were exported 
for analysis.
Histological and immunohistochemical analysis
Fixed hearts were embedded in paraffin and sectioned 
(7 μm). For quantification of fibrosis, deparaffinised and 
rehydrated sections were stained with Direct Red 80/
Fast green in aqueous picric acid. Four fields of view were 
scored from the LV of each mouse by an investigator 
blind to genotype (0 = no interstitial collagen; 1 = subtle 
traces of interstitial collagen; 2 = clearly visible thin 
strands of interstitial collagen; 3 = thicker, more numerous 
strands of interstitial collagen; 4 = severe focal patches 
of interstitial collagen deposition in addition to thick 
interstitial collagen strands). To measure cardiomyocyte 
cross-sectional area, sections were stained with Isolectin 
B4 (1:100; I21414 Thermo Fisher Scientific) followed 
by streptavidin Alexa 488 (1:100; S32354 Thermo 
Fisher Scientific) in combination with rhodamine-
conjugated wheat germ agglutinin (1:1000; RL-1022 
Vector Laboratories, Peterborough, UK) and DAPI. 
Cardiomyocytes were counted and measured using Adobe 
Photoshop CS5. To assess cardiomyocyte proliferation 
in neonatal hearts, sections were stained with anti-
Cardiac Troponin T (1F11) (1:200; ab10214 Abcam) in 
combination with anti-Ki67 (1:200; ab15580 Abcam). 
Flurophore-conjugated secondary antibodies (Alexa 
Fluor, Invitrogen) were used to detect immunostaining. 
The percentage of Ki67-positive cardiomyocytes was 
calculated using Adobe Photoshop CS5.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
6 software. The impact of genotype on the survival of 
mice was assessed using the Chi-square test. Comparisons 
between two groups were made using an unpaired t-test. 
For analysis of two factors, a two-way ANOVA was carried 
out with multiple comparisons made using the Tukey 
post hoc test. Values are means ± s.e.m. with P < 0.05 
deemed significant.
Results
SMGRKO mice lack glucocorticoid receptor expression  
in cardiomyocytes and VSM and show reduced  
early-life survival
The SM22α-Cre transgene used to produce SMGRKO mice 
is transiently expressed in cardiomyocytes as well as in 
VSM (Li et al. 1996). We have previously shown that GR 
protein and mRNA levels are reduced in whole hearts of 
foetal SMGRKO (Cre+) mice (Rog-Zielinska  et  al. 2013). 
Consistent with this, levels of GR protein and mRNA 
were reduced in hearts of adult SMGRKO mice compared 
with controls (Left ventricle, LV). In accordance with the 
known activity of SM22α-Cre in VSM cells, levels of Nr3c1 
mRNA (encoding GR) were also reduced in the aorta of 
SMGRKO mice (Fig. 1C). Immunohistochemical staining 
showed that the reduction in LV GR protein levels is in 
cardiomyocytes and VSM cells (Fig. 1D). Levels of mRNA 
encoding the GR target gene, FK506-binding protein-5 
(Fkbp5), were reduced in LV of SMGRKO mice compared 
with those in controls (Fig. 1B), consistent with reduced 
GR signalling in hearts of SMGRKO mice.
Although foetal SMGRKO mice do not deviate 
from the expected 50% Mendelian ratio at embryonic 
day (E)17.5 (Rog-Zielinska  et  al. 2013), by weaning (at 
3 weeks of age) SMGRKO mice were only 40% of the total 
male and 36% of the total female population (males: 
SMGRKO = 94 vs control = 142, chi-squared test P < 0.01; 
females: SMGRKO = 92 vs control = 163; chi-squared test 
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Figure 1
Adult SMGRKO mice lack glucocorticoid receptor expression in cardiomyocytes and vascular smooth muscle cells. Left ventricles (LV) and aorta were 
collected from 12-week-old SMGRKO mice (black/hatched bars) and control littermates (white bars). (A) Western blotting shows NR3C1 (GR) protein 
levels (relative to internal control β-actin) are reduced in LV of male SMGRKO mice (N = 5–6). (B) Quantitative RT-PCR shows reduced levels of mRNA 
encoding GR (Nr3c1) and FK506-binding protein 5 (Fkbp5) in LV of male and female SMGRKO mice, compared to controls (N = 9–12). (C) Levels of Nr3c1 
mRNA are reduced in aortas of male SMGRKO mice compared to those in controls (N = 7–9). (D) Representative images of immunohistochemical staining 
of GR (brown DAB staining) in LV of male SMGRKO mice. Circles indicate examples of cardiomyocytes lacking GR and arrows indicate vascular smooth 
muscle cells lacking GR. Cardiomyocytes cut in the short axis were scored for the presence or absence of GR staining (8 fields of view/heart) (N = 6–7). 
Data are means ± s.e.m. and were analysed using an unpaired t-test. ***P < 0.001, ****P < 0.0001.
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P < 0.0001. This suggests that only 66% of male and 
56% of female SMGRKO mice survive weaning. Very few 
deaths occurred following recording of litters (normally 
within 1  day of birth) suggesting that deaths occur in 
late gestation or shortly after birth. Following weaning, 
survival was similar between SMGRKO and control mice.
Systolic cardiac function is impaired in adult  
SMGRKO mice
High-resolution ultrasound was used to assess the 
functional consequence of reduced GR expression 
in cardiomyocytes and VSM in adult mice. Doppler 
measurements of blood flow across the mitral valve showed 
a detrimental increase in the myocardial performance 
index (MPI, a measure of combined systolic and diastolic 
function) in 10-week-old male SMGRKO mice (P < 0.05), 
with a strong trend for an increase in MPI in females 
(P = 0.062, Fig.  2). Assessment of the component parts 
of the MPI showed that elongation of the isovolumetric 
contraction time underlies the elevation in MPI in both 
male and female SMGRKO mice (Fig. 2B and Supplementary 
Table 2). Thus, the increase in LV isovolumetric contraction 
time previously observed in SMGRKO mice in utero (Rog-
Zielinska et al. 2013) persists into adulthood. In contrast, 
there were no genotype differences in E/A wave ratio 
(the ratio of the early (E) to the later atrial (A) ventricular 
filling velocities), early diastolic deceleration or mitral 
deceleration index (MDI) in adulthood (Supplementary 
Table 2), suggesting that the impairment in heart function 
is restricted to the early phase of contraction. Stroke 
volume was higher in male SMGRKO mice compared with 
that in controls (Supplementary Table 3), but this likely 
reflects a difference in heart size (see below), rather than 
function, as ejection fraction was equivalent between 
SMGRKO mice and controls, for both males and females 
(Supplementary Table 3).
Glucocorticoids can influence vascular tone 
(Whitworth et al. 1989, Pirpiris et al. 1992, Goodwin et al. 
2008) and both hypothalamic–pituitary–adrenal axis 
activity and blood pressure are elevated in mice that 
are GR haploinsufficient (Michailidou  et  al. 2008). In 
SMGRKO mice, mean systolic blood pressure did not differ 
from controls (Supplementary Tables 4 and 5), consistent 
with previous findings in mice with VSM deletion of GR 
(Goodwin et al. 2008). Similarly, there were no genotype 
differences in plasma corticosterone levels (morning 
and evening) or adrenal gland weight (Supplementary 
Tables 4 and 5).
Cardiac remodelling in SMGRKO mice
Heart weight was increased in male and female SMGRKO 
mice at 12  weeks of age (Fig.  3A). Body weight did 
not differ from controls (Supplementary Tables  4 
and 5). To examine whether this associates with 
cellular hypertrophy, cardiomyocyte cross-sectional 
area was measured. Male SMGRKO mice showed a 
right shift in the cardiomyocyte cross-sectional area 
frequency distribution, towards larger cardiomyocytes, 
Figure 2
Doppler measurements of blood flow across the mitral valve within the LV show impaired cardiac function in 10-week-old SMGRKO mice. (A) Schematic 
representation of a Doppler trace indicating isovolumetric contraction time (IVCT), ejection time (ET) and isovolumetric relaxation time (IVRT) used to 
derive the myocardial performance index (MPI). Representative Doppler traces highlight the elongated IVCT in SMGRKO mice, compared to littermate 
controls (circled). (B) Elongation of the IVCT underlies the detrimental elevation in MPI in 10-week-old SMGRKO mice (black/hatched bars) compared to 
littermate controls (white bars) (N = 11–16). Data are means ± s.e.m. and were analysed using an unpaired t-test. *P < 0.05, **P < 0.01.
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at 12  weeks (Fig.  3B and Supplementary Fig.  1A). 
Consistent with cardiomyocyte hypertrophy, levels of 
mRNA encoding myosin heavy chain (MHC) beta (Myh7), 
the foetal myosin heavy chain isoform and a marker of 
pathological hypertrophy (Swynghedauw 1986), were 
elevated in the LV of male mice at 12 weeks (Fig. 3C). In 
contrast, 12-week-old female SMGRKO mice showed a left 
shift in the cardiomyocyte cross-sectional area frequency 
distribution, towards smaller cardiomyocytes, (Fig. 3B and 
Supplementary Fig. 1A) and LV levels of mRNA encoding 
Myh7 did not differ from controls (Fig.  3C). Moreover, 
cardiomyocyte volume, measured in female mice using 
the perforated patch technique to carry out voltage clamp 
on isolated cells, was similar between SMGRKO mice and 
their controls (Supplementary Fig. 1B). This confirms that 
the increase in heart weight in adult female mice is not due 
to cardiomyocyte hypertrophy. We next tested whether 
cardiomyocyte hypertrophy is present in younger male 
SMGRKO mice. Cardiomyocyte cross-sectional area in 
6-week-old male SMGRKO mice was identical to that in 
control mice, and Myh7 mRNA levels were normal, despite 
increased heart weight (Fig. 4), consistent with the idea 
that cardiomyocyte hypertrophy is not the primary cause 
of the elevated heart weight in male or female SMGRKO 
mice. Increased cardiomyocyte cross-sectional area 
associated with elevated levels of Myh7 in 12-week-old 
male SMGRKO mice suggests cardiomyocyte hypertrophy 
arises secondarily, perhaps in response to the increase in 
cardiac workload at puberty, which is greater in males.
SMGRKO mice develop LV cardiac fibrosis
To investigate whether the increased isovolumetric 
contraction time and/or cardiomyocyte hypertrophy in 
adult male SMGRKO mice are associated with cardiac 
fibrosis, picrosirius red was used to stain collagen. 
Compared to controls, staining of interstitial collagen was 
increased in hearts of 12-week-old male SMGRKO mice 
Figure 3
Heart weight is elevated in SMGRKO mice, with male SMGRKO mice showing evidence of pathological cardiomyocyte hypertrophy. Hearts of 12-week-
old SMGRKO mice (black/hatched bars) and control littermates (white bars) were examined. (A) Heart weight (normalised for body weight) is elevated in 
male and female SMGRKO mice, compared with their respective littermate controls (N = 9–11). (B) Representative images of formalin-fixed, paraffin-
embedded sections of LV of male and female SMGRKO mice and littermate controls showing wheat germ agglutinin staining of plasma membrane (red), 
isolectin B4 staining of the vasculature (green) and DAPI staining of nuclei (blue). The frequency distribution for cardiomyocyte cross-sectional area is 
right shifted, towards larger cardiomyocytes, in male SMGRKO mice (green line) but left shifted, towards smaller cardiomyocytes, in female SMGRKO 
mice (pink line) vs their respective controls (black lines). N = 8–10; 40 cardiomyocytes measured/heart. (C) Levels of mRNA encoding markers indicative of 
pathological cardiac remodelling, including myosin heavy chain alpha (Myh6), myosin heavy chain beta (Myh7) and atrial natriuretic peptide (Nppa), 
were not altered in LV of female SMGRKO mice. In contrast, levels of mRNA encoding Myh7 were elevated in LV of male SMGRKO mice. N = 8–12. 
Data are means ± s.e.m. and were analysed using an unpaired t-test, *P < 0.05, ***P < 0.001.
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Figure 5
SMGRKO mice develop left ventricular cardiac 
fibrosis. Representative images of picrosirius red/
fast green-stained sections of formalin-fixed 
paraffin-embedded hearts from SMGRKO mice 
and littermate controls (A, B and C). Assessment 
of picrosirius red staining of collagen in LV of 
SMGRKO mice (black/hatched/striped bars) 
compared with controls (white bars). Four fields 
of view were scored from the LV of each mouse 
by an investigator blind to genotype (scoring 
system described in ‘Materials and methods’ 
section). (A) 12-week-old males and females 
(N = 7–10). (B) 6-week-old males (N = 10). 
(C) 2-day-old males and females (N = 8–10). 
Data are means ± s.e.m. and were analysed using 
unpaired t-tests. *P < 0.05, ***P < 0.001.
Figure 4
Heart weight is elevated in 6-week-old male 
SMGRKO mice, but there is no evidence of 
pathological cardiomyocyte hypertrophy. 
(A) Heart weight is elevated in 6-week-old male 
SMGRKO mice (black bar) compared with 
littermate controls (white bar) (N = 10–11). 
(B) Levels of mRNA encoding markers indicative 
of pathological cardiac remodelling, including 
myosin heavy chain alpha (Myh6), myosin heavy 
chain beta (Myh7) and atrial natriuretic peptide 
(Nppa), were not altered in LV of 6-week-old 
male SMGRKO mice compared with controls 
(N = 10–11). (C) Representative images of 
formalin-fixed, paraffin-embedded sections of LV 
of 6-week-old male SMGRKO mice and controls 
showing wheat germ agglutinin staining of 
plasma membrane (red), isolectin B4 staining of 
the vasculature (green) and DAPI staining of 
nuclei (blue). The frequency distribution for 
cardiomyocyte cross-sectional area did not differ 
in SMGRKO mice (blue line) compared with 
controls (black line). N = 10; 40 cardiomyocytes 
measured/heart. Data are means ± s.e.m. and were 
analysed using an unpaired t-test, *P < 0.05.
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(Fig. 5A). Females also showed an increase in interstitial 
collagen (Fig.  5A). The increase in collagen staining in 
both genders suggests it is not related to cardiomyocyte 
hypertrophy, which only occurred in males. To test 
whether pro-fibrotic signalling is elevated in adult 
SMGRKO mice, RNA from LV of 12-week-old males and 
females was subject to profiling using a Qiagen Mouse 
Fibrosis RT² Profiler PCR Array. Levels of mRNA encoding 
pro-fibrotic markers and extracellular matrix remodelling 
proteins were increased in SMGRKO mice compared 
with controls (Supplementary Table 6). Levels of mRNA 
encoding platelet-derived growth factor alpha (Pdgfa), 
implicated in fibroblast proliferation, and alpha smooth 
muscle actin (Acta2), a marker of myofibroblast activation 
were also elevated (Supplementary Table 6). Quantitative 
RT-PCR confirmed higher levels of mRNA encoding 
transforming growth factor beta-1 (Tgfb1), connective 
tissue growth factor (Ctgf), collagen type 1α2 (Col1a2) 
and collagen type 3α1 (Col3a1) in LV of 12-week-old male 
SMGRKO mice compared to controls (Fig.  6A), though 
only the increase in Col1a2 mRNA levels was significant 
in 12-week-old female SMGRKO mice. Similarly, 
quantitative RT-PCR confirmed higher expression of 
matrix remodelling genes in LV of adult male and female 
SMGRKO mice (Supplementary Fig. 2). In both genders, 
this was associated with elevated levels of Nr3c2 mRNA, 
encoding MR. This suggests elevated MR signalling, 
possibly to compensate for reduced GR signalling, may 
Figure 6
Levels of mRNA encoding pro-fibrotic genes are 
elevated in the LV of SMGRKO mice. 
(A) Quantitative RT-PCR measurements of mRNA 
show upregulation of pro-fibrotic genes, 
including transforming growth factor beta-1 
(Tgfb1); connective tissue growth factor (Ctgf); 
collagen type 1α2 (Col1a2) and collagen type 3α1 
(Col3a1) in LV of SMGRKO mice (black/hatched/
striped bars) compared with controls (white bars). 
Measurements were made in male mice aged 
6 weeks and both sexes at 12 weeks. Data are 
pooled from 2-day-old male and female mice. 
(B) Levels of Nr3c2 mRNA (encoding MR) are 
elevated at 6 and 12 weeks, but not at 2 days, in 
LV of SMGRKO mice compared with controls. 
Data are means ± s.e.m. and were analysed using 
unpaired t-tests, n = 10–11, *P < 0.05, **P < 0.01.
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drive the pro-fibrotic cardiac phenotype of SMGRKO 
mice. Expression of cytokines and chemokines associated 
with inflammation, including tumour necrosis factor 
(Tnf) and interleukin 1 beta (Il1b), remained unchanged 
in LV of SMGRKO mice (Supplementary Table 6). Thus, 
fibrosis does not appear to be secondary to ongoing 
inflammation. Picrosirius red staining showed interstitial 
collagen levels were already raised in LV of 6-week-
old male SMGRKO mice (Fig.  5B), and this was again 
associated with elevated levels of Col1a2 (Fig.  6A) and 
Nr3c2 mRNA (Fig. 6B). Importantly, there was no increase 
in cardiac collagen staining, pro-fibrotic markers or Nr3c2 
mRNA levels in 2-day-old SMGRKO mice (Figs 5C and 6) 
suggesting that the fibrotic phenotype develops after the 
neonatal period.
Spironolactone attenuates pro-fibrotic gene expression 
but does not prevent cardiac fibrosis in SMGRKO mice
To test whether MR antagonism can alleviate the 
pathological cardiac phenotype of SMGRKO mice, 
spirono lactone was administered from birth. 
Spironolactone treatment decreased renal expression 
of the classical corticosteroid target genes, Serine/
threonine-protein kinase (Sgk1) (Ueda  et  al. 2014) and 
Fkbp5 in both genotypes (Supplementary Fig. 3A and B), 
confirming MR antagonism. Spironolactone did not 
prevent the development of cardiac fibrosis in male 
SMGRKO mice (Fig.  7A and B) though it did modestly 
attenuate the increase in Col1a2 mRNA levels, whilst 
having no effect in control mice (Fig. 7B). This suggests 
that cardiac fibrosis in SMGRKO mice can be only partly 
attributed to activation of MR. Interestingly, although 
spironolactone treatment had no effect on the age-
related increase in body weight of either SMGRKO or 
control mice (as expected) (Supplementary Fig.  3C), it 
caused a modest reduction in heart weight at 8  weeks 
of age compared with vehicle treatment, irrespective 
of genotype (Fig. 7C and Supplementary Fig. 3D). This 
implicates a role for MR signalling in postnatal cardiac 
growth independent of GR.
Figure 7
Spironolactone attenuates the increase in pro-fibrotic gene expression in male SMGRKO mice. Representative images of picrosirius red/fast green 
staining of sections of formalin fixed paraffin embedded hearts from male SMGRKO mice and control littermates treated from birth with the MR 
antagonist spironolactone or vehicle. Assessment of picrosirius red staining in 8-week-old mice shows that spironolactone treatment (chequered bars) 
did not prevent the increase in interstitial collagen in LV of SMGRKO mice compared to vehicle-treated controls (white bars). 4 fields of view were scored 
from the LV of each mouse by an investigator blind to genotype (scoring system described in ‘Materials and methods’ section) (N = 10–11). (B) Levels of 
mRNA-encoding collagen type 1α2 (Col1a2) and collagen type 3α1 (Col3a1) were measured in LV of 8-week-old mice. Spironolactone attenuated the 
increase in Col1a2 mRNA levels in SMGRKO mice (N = 10–13). (C) Heart weight, expressed relative to body weight, was increased in 8-week-old male 
SMGRKO mice compared with controls, irrespective of spironolactone treatment. Spironolactone reduced heart weight in both genotypes compared 
with vehicle treated mice (N = 10–18). Data are means ± s.e.m. and were analysed by two-way ANOVA (boxes) followed by Tukey’s multiple comparisons 
test, * or #P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. *Genotype effect relative to control. #Spironolactone effect, relative to vehicle.
447Research r v richardson and others Cardiovascular role of GR
DOI: 10.1530/JOE-16-0458
Jo
u
rn
al
o
f
En
d
o
cr
in
o
lo
g
y
http://joe.endocrinology-journals.org © 2017 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
232:3
Discussion
Our findings suggest complex roles for GR signalling in 
cardiac function, growth and remodelling. Whether these 
are interdependent or not is currently unclear. The modest 
impairment in systolic function in adult male and female 
SMGRKO mice, reflected in the elongated isovolumetric 
contraction time, is already present in foetal life when 
SMGRKO heart size is normal (Rog-Zielinska et al. 2013). 
Whilst the mechanism underlying the increase in 
isovolumetric contraction time is currently unknown, 
these findings suggest impaired systolic function is a 
primary and early manifestation of GR deficiency in 
cardiomyocytes, whereas the increase in heart size arises 
later. Whether aspects of the phenotype, particularly 
cardiac fibrosis, arise secondarily to the impaired systolic 
function is an important question for the future. It is also 
possible that the elongated isovolumetric contraction time 
(and/or cardiac immaturity, observed in late gestation 
SMGRKO foetuses (Rog-Zielinska  et  al. 2013)) may be 
causally related to the reduction in perinatal survival of 
SMGRKO mice.
Surviving SMGRKO mice have enlarged hearts. The 
increase in heart weight in the absence of cardiomyocyte 
hypertrophy in female and in young male SMGRKO mice 
suggests an increase in cell number, either cardiomyocytes 
or fibroblasts may contribute to the increase in heart 
weight. This most likely arises postnatally as foetal SMGRKO 
hearts are the same size as those of control mice at E17.5 
(Rog-Zielinska et al. 2013). A role for GR in controlling heart 
growth in infancy is inferred by the observation that a GR 
gene polymorphism, linked with relative glucocorticoid 
resistance, associates with increased LV mass and systolic 
blood pressure in childhood (Geelhoed  et  al. 2011). 
SMGRKO mice have normal blood pressure, suggesting 
their increased heart weight is not a result of hypertension. 
Plausibly, the cardiac hypertrophy of SMGRKO mice may 
reflect greater cellularity. This could potentially arise from 
a prolonged period of cardiomyocyte proliferation in 
neonates, thereby increasing cardiomyocyte endowment. 
Consistent with this notion, preliminary data in hearts 
of 2-day-old SMGRKO mice showed an increase in the 
number of Ki67+ cardiomyocytes, compared to littermate 
controls (Supplementary Fig.  4) suggesting increased or 
prolonged proliferation. Interestingly, spironolactone 
antagonism of MR reduced heart weight in control as well 
as SMGRKO mice, suggesting MR activation normally 
promotes heart growth. However, as knock-out of MR 
in cardiomyocytes has little effect on the basal heart 
phenotype (Fraccarollo  et  al. 2011, Lother  et  al. 2011), 
this  effect may be mediated indirectly. Nevertheless, 
previous data support a role for MR in early life cardiac 
growth. In neonatal rats, spironolactone was found 
to impair cardiac growth by reducing the number of 
proliferating cardiomyocytes (Sohn  et  al. 2010). In 
contrast, activation of MR by cortisol in foetal sheep 
increased cardiac cell proliferation (Feng et al. 2013). Given 
the critical role of GR signalling in cardiac maturation 
(Rog-Zielinska et al. 2014b), it is possible that the GR:MR 
balance may determine the effect of corticosteroids 
on cardiac growth in early life. This may, in turn, have 
consequences for cardiac health in adulthood. Whether 
GR activation (or the GR:MR balance) limits early heart 
growth (and cardiomyocyte endowment) by promoting 
the neonatal switch in cardiomyocytes from proliferative 
to hypertrophic growth merits investigation in the future.
Cardiomyocyte hypertrophy, associated with elevated 
LV expression of Myh7, occurred in adult male but not 
female SMGRKO mice. Moreover, it only became manifest 
in male SMGRKO mice after puberty. It is well known that 
adult male hearts are hypertrophied relative to female, 
with this ascribed to direct effects in cardiomyocytes as 
a result of the rise in androgen levels at puberty in males 
(Koenig et al. 1982, de Simone et al. 1995, Marsh et al. 1998, 
Leinwand 2003). Myocardial remodelling in response to 
pathological or physiological stimuli also differs between 
male and female hearts (Piro  et al. 2010). In rats, when 
cardiac remodelling was induced by pressure overload, 
there was a greater increase in mRNA encoding Myh7 
in the LV of males than that in females (Weinberg et al. 
1999). Our data are consistent with this gender difference 
in susceptibility to cardiac remodelling and suggest 
that GR deficiency in cardiomyocytes and/or vascular 
smooth muscle cells potentiates the hypertrophic actions 
of androgens in pubertal males. Whether SMGRKO 
mice show a gender-specific difference in models of 
hypertrophic cardiac disease, for example with pressure-
overload, will be important to establish and may provide 
insight into the role glucocorticoid action plays in gender 
differences in susceptibility to heart disease.
Both male and female SMGRKO mice develop 
interstitial cardiac fibrosis. This arises postnatally, with 
no increase in pro-fibrotic gene signalling evident in 
neonates. In both genders, interstitial fibrosis is associated 
with increased expression of genes encoding collagen and 
matrix remodelling enzymes, as well as Acta2, a marker of 
myofibroblast activation (Darby et al. 1990). Interestingly, 
the array data showed gender differences in the level of 
expression of a number of genes associated with fibrosis, 
including Acta2, suggesting there may be a gender 
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difference in fibrotic response to cardiac injury in these 
mice. MR expression was increased in hearts of adult 
SMGRKO mice. This is unlikely to be direct compensation 
for lack of GR, levels in neonatal hearts were normal 
and MR expression is reduced (rather than increased) in 
another GR-knockout model (Meijer et al. 1997). Elevated 
MR expression has been suggested to drive cardiac fibrosis 
(Lother  et  al. 2011), and MR antagonism is protective 
in murine models of pressure-overload (Kuster  et  al. 
2005) and post-MI remodelling (Fraccarollo et al. 2003). 
However, antagonism of MR from birth had only a 
modest effect on cardiac fibrosis in SMGRKO mice, so 
whilst a possible contributor, MR activation does not 
appear to be the primary driver of the fibrosis. At present, 
it is unclear what the underlying cause is. There is no 
evidence of inflammation in the hearts of SMGRKO 
mice, which showed similar expression to control mice 
of a range of cytokine and chemokine mRNAs. The lack 
of overt inflammation is also consistent with unaltered 
circulating glucocorticoid levels in SMGRKO mice, which 
would be expected to increase with cardiac inflammation. 
Plausibly, the fibrosis could result from mechanical stress 
related to the elongated isovolumetric contraction time. 
Although little myocardial deformation occurs during 
isovolumetric contraction, there is circumferential 
stretch in the subepicardial layer and circumferential 
shortening in the midwall and subendocardial layer 
(Ashikaga et al. 2009). Foetal SMGRKO mice show altered 
cardiac ultrastructure, including the organisation of the 
outermost circumferential muscle layer. This suggests 
contractile abnormalities in cardiomyocytes in utero that 
persist into adulthood may activate repair pathways 
postnatally to cause fibrosis.
The cardiac phenotype of SMGRKO mice shows 
similarities, but also some differences, to that of mice with 
MHCα-Cre mediated deletion of GR in cardiomyocytes, 
termed CardioGRKO mice (Oakley et al. 2013). Similarities 
confirm the role of cardiomyocyte GR, whereas 
differences are likely to relate to temporal differences in 
Cre transgene expression or to the tissue specificity of 
the GR deletion: in cardiomyocytes and vascular smooth 
muscle in SMGRKO mice, but restricted to cardiomyocytes 
in CardioGRKO mice. Both CardioGRKO and SMGRKO 
mice show a relatively high mortality rate, but the 
timing differs. In both, females show a higher mortality 
than males. The normal Mendelian ratio of SMGRKO 
mice at E17.5 (Rog-Zielinska  et  al. 2013), but deviance 
from this following birth, suggests SMGRKO mice die 
in late gestation or around the time of birth (there are 
no excess deaths after the neonatal period). In contrast, 
CardioGRKO mice are born at the expected Mendelian 
ratio yet die prematurely of congestive heart failure. 
This difference in timing of death is likely to reflect the 
late gestation expression of the MHCα-Cre transgene in 
ventricular cardiomyocytes (Lyons et al. 1990), compared 
to the earlier and transient expression of the Sm22α-Cre 
transgene. Thus, CardioGRKO mice may retain sufficient 
GR in cardiomyocytes to survive the high demand on the 
heart during and shortly after birth, whereas SMGRKO 
mice appear vulnerable at birth.
Both SMGRKO and CardioGRKO mice have larger 
hearts than their respective controls. Cardiomyocyte 
hypertrophy occurred in adult SMGRKO and CardioGRKO 
mice, associated with an increase in Myh7 mRNA. In 
SMGRKO mice, this was restricted to males (the gender 
of CardioGRKO mice was not specified). In CardioGRKO 
mice, cardiomyocyte hypertrophy preceded heart failure 
and premature death (Oakley  et  al. 2013), but there 
was no excess mortality in SMGRKO mice after the 
immediate neonatal period. The lack of progression to 
heart failure in SMGRKO mice suggests that heart failure 
is not an inevitable consequence of GR deficiency in 
cardiomyocytes. It remains possible that the SMGRKO 
mice that survive to weaning and the CardioGRKO mice 
that do not go on to develop heart failure have residual GR 
expression in cardiomyocytes. Alternatively, GR deficiency 
may potentiate the genotoxic effects associated with the 
continuing high expression of MHCα-Cre (Buerger  et  al. 
2006) in CardioGRKO mice, which are otherwise only 
apparent at a sub-clinical level. In contrast, Sm22α-Cre 
is only transiently expressed in cardiomyocytes during 
development and Cre is absent in adult cardiomyocytes 
(Li  et  al. 1996). Whilst we have not formally ruled out 
a postnatal cardiac phenotype solely due to transient 
expression of Cre during development, we have used the 
same line of SM22-Cre transgenic mice to disrupt Hsd11b1 
expression, with no discernible effect on either cardiac 
size or the response to cardiac injury (White et al. 2015).
CardioGRKO mice showed a strong cardiac 
inflammatory response by 2 months of age, which we did 
not observe in SMGRKO mice. In contrast, SMGRKO mice 
showed a fibrotic response, not observed in CardioGRKO 
mice. These differences are likely to relate to the Cre 
used to delete GR in cardiomyocytes. It is possible that 
GR deletion in other cell types such as vascular smooth 
muscle cells is responsible for the cardiac fibrosis of 
SMGRKO mice. Interestingly, expression of Acta2, a 
marker of myofibroblast activation, was increased in 
CardioGRKO mice as well as SMGRKO mice, though in 
CardioGRKO mice this was not associated with elevated 
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collagen expression. In contrast, the lack of evidence for 
an inflammatory response in hearts of SMGRKO mice 
suggests that the inflammation seen in CardioGRKO mice 
is secondary to the pathological cardiomyocyte changes 
that lead to heart failure in these mice.
Recent studies have made progress in elucidating 
the individual roles of GR and MR signalling in specific 
cardiovascular cell types (Oakley & Cidlowski 2015, Young 
& Rickard 2015, Richardson  et  al. 2016). Here, we have 
provided further evidence for a critical requirement for 
GR in myocytes in the cardiovascular system. SMGRKO 
mice may prove to be a useful new model to investigate 
the mechanisms that give rise to cardiac fibrosis without 
alteration in blood pressure or invoking pharmacological 
activation of MR. The absence of maladaptive 
cardiomyocyte hypertrophy in female SMGRKO mice 
highlights the necessity to investigate sex differences in 
cardiovascular research studies. Future research needs to 
address the relationship between MR and GR signalling 
to elucidate the consequences of alterations in the 
GR:MR balance across the range of cardiac cell types. 
This will provide essential insight into the cell-specific 
role of corticosteroids, both in early life programming 
of cardiomyocyte endowment and in subsequent cardiac 
pathology, in order to open up avenues for therapeutic 
manipulation of corticosteroid signalling.
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